About Regeneron
Funding & Growth
✓ Pros
- • Strong drug pipeline
- • Excellent genetics research
- • Founder-led company
- • Good compensation
- • Stable financials
✗ Cons
- • Tarrytown, NY location
- • Less startup-like culture
- • Some siloed teams
- • Traditional pharma aspects
🏢 Working Here
Regeneron's Tarrytown, NY campus (Westchester County, north of NYC) houses one of the most data-rich environments in pharma.
The company's VelociGene technology and massive target validation efforts generate extraordinary datasets.
Bioinformaticians work in Genome Informatics, Computational Sciences, or embedded in therapeutic area teams (Ophthalmology, Immunology, Oncology).
A typical role involves analyzing mouse model genomics data, human genetics for target validation, clinical trial biomarkers, and antibody engineering.
Regeneron's culture emphasizes scientific rigor and publication - the company produces high-impact papers regularly.
Collaboration with top academic centers (Columbia, Mt.
Sinai, Weill Cornell) is common.
The Westchester location offers excellent schools and lower cost of living than NYC while remaining accessible to the city.
🧬 Bioinformatics Focus
Regeneron's computational biology spans genetics-driven drug discovery and antibody therapeutics. Core areas:
- Human genetics - RGC analyzes UK Biobank, Geisinger MyCode, and proprietary cohorts for target validation,
- Mouse model genomics - analyzing VelociGene knockout mice at scale to predict drug efficacy and safety,
- Antibody engineering - computational design and optimization of therapeutic antibodies,
- Multi - omic integration - combining genetics, transcriptomics, proteomics, and clinical data for target prioritization,
- Clinical biomarkers - identifying patient populations for drugs like Eylea (AMD), Dupixent (atopic dermatitis), Libtayo (cancer). The team has pioneered approaches in rare variant analysis, gene burden testing, and polygenic risk scores. Notable projects include discovering ANGPTL3 as a cardiovascular target and PCSK9 inhibitors. Computational challenges include biobank-scale analysis, integrating diverse data types, and translating genetic findings into actionable drug targets.
🔬 Regeneron Genetics Center (RGC)
The Regeneron Genetics Center (RGC) is one of the world's largest human genetics research initiatives, combining cutting-edge genomic sequencing with massive biobank partnerships to discover new drug targets.
- • Sequenced 2+ million exomes - one of the largest datasets in pharma
- • Key partnerships: UK Biobank (500K participants), Geisinger Health System (MyCode)
- • Pioneered exome sequencing at biobank scale for drug discovery
- • Discoveries led to drugs targeting PCSK9, ANGPTL3, and other novel targets
- • Published 100+ high-impact papers in Nature, Science, NEJM
Focus Areas
📈 Career Growth & Development
Career Paths
Scientific Track
Compensation
Competitive compensation packages include strong bonuses (up to 25% of base) and restricted stock units.
Development
Regeneron strongly supports professional development through conference attendance, external collaborations, and publications in top journals.
Mobility
The company promotes from within, and alumni often move to other antibody companies, genetics startups, or top academic positions.
Culture
Regeneron values both deep expertise and broad cross-functional impact, with internal seminars featuring world-renowned speakers.
💊 Top Medicines & Blockbuster Drugs
DUPIXENT (dupilumab)
Indication: Atopic dermatitis, asthma, chronic rhinosinusitis, eosinophilic esophagitis, COPD
Blockbuster - fastest growing biologic
Annual Revenue (USD)
EYLEA / EYLEA HD (aflibercept)
Indication: Wet AMD, diabetic macular edema, diabetic retinopathy
Leading retinal disease treatment (global sales incl. Bayer)
Annual Revenue (USD)
LIBTAYO (cemiplimab)
Indication: Cutaneous squamous cell carcinoma, basal cell carcinoma, lung cancer
PD-1 checkpoint inhibitor - growing 40%+ annually
Annual Revenue (USD)
PRALUENT (alirocumab)
Indication: High cholesterol, cardiovascular disease prevention
PCSK9 inhibitor - discovered via RGC genetics
Annual Revenue (USD)
KEVZARA (sarilumab)
Indication: Rheumatoid arthritis
IL-6 receptor antagonist
Annual Revenue (USD)
EVKEEZA (evinacumab)
Indication: Homozygous familial hypercholesterolemia
ANGPTL3 inhibitor - discovered via RGC genetics
Annual Revenue (USD)
INMAZEB (atoltivimab/maftivimab/odesivimab)
Indication: Ebola virus infection
First FDA-approved Ebola treatment (limited market)